Risk adjusted net present value: What is the current valuation of Incyte’s Epacadostat?

Epacadostat is a small molecule commercialized by Incyte, with a leading Phase II program in Salivary Gland Cancer.

£30M clinical study will enhance the understanding of NASH cirrhosis

The most extensive clinical study into liver cirrhosis ever conducted worldwide has been announced by Newcastle University, University of Edinburgh and leading research-driven global biopharmaceutical

January 9, 2024

Prescription for resilience: Health care needs financial sector-inspired regulation

In the early days after it was hit by a cyberattack on Feb. 21, Change Healthcare, one of the country’s largest claims and prescription processors,

March 14, 2024

Injectables manufacturing ushers in a new era of accessibility – Pharmaceutical Technology

Image credit: Shutterstock/Chekunov Aleksandr The pharmaceutical injectables market is gaining more traction as vaccines and the development of biological drugs such as cell and gene

November 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.